1. 153OResponse rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial. (13th May 2019) Authors: Loibl, S; Conte, P F; Campone, M; Mayer, I; Lu, Y-S; Denduluri, N; Wilke, C; Ridolfi, A; André, F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. (23rd October 2018) Authors: Conte, P F; Guarneri, V; Bisagni, G; Piacentini, F; Brandes, A A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Frassoldati, A; Musolino, A; Garrone, O; Taverniti, C; Rimanti, A; Sarti, S; Rubino, D; Bologna, A; Vicini, R; Balduzzi, S; D'Amico, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 88OValidation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial. (13th May 2019) Authors: Dieci, M V; Bisagni, G; Brandes, A A; Frassoldati, A; Donadio, M; Garrone, O; Piacentini, F; Balduzzi, S; Guarneri, V; Conte, P F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. (18th February 2019) Authors: Guarneri, V; Dieci, M V; Bisagni, G; Frassoldati, A; Bianchi, G V; De Salvo, G L; Orvieto, E; Urso, L; Pascual, T; Paré, L; Galván, P; Ambroggi, M; Giorgi, C A; Moretti, G; Griguolo, G; Vicini, R; Prat, A; Conte, P F Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 921 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Estimated direct costs of non-small-cell lung cancer by stage and care phase: a whole disease model. (30th September 2020) Authors: De Luca, G; Buja, A; Rivera, M; De Polo, A; Marchetti, M; Scioni, M; Pasello, G; Bortolami, A; Schiavon, M; Conte, P F Journal: European journal of public health Issue: Volume 30(2020)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial. (13th May 2019) Authors: Guarneri, V; Cinieri, S; Orlando, L; Bengala, C; Mariani, G; Bisagni, G; Frassoldati, A; Zamagni, C; Salvo, G De; Conte, P F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗